<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873950</url>
  </required_header>
  <id_info>
    <org_study_id>13-011D</org_study_id>
    <secondary_id>SCR-002</secondary_id>
    <nct_id>NCT01873950</nct_id>
  </id_info>
  <brief_title>Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spaulding Clinical Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Food and Drug Administration (FDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their
      effects on electrophysiological and other clinical parameters. The underlying purpose is to
      determine if depolarization and repolarization effects caused by drugs with differing ionic
      channel mechanisms can be distinguished from one another, and to gauge the sensitivity and
      specificity of novel signal analyses for detection of depolarization and repolarization
      changes. Secondarily, to evaluate the exposure response relationship and drug induced effects
      on the heart rate biomarker relationship.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double blind, 5 way crossover research study in healthy male and
      female subjects, 18 to 35 years of age, to compare 4 known QT prolonging drugs versus placebo
      to determine their effects on electrophysiological and other clinical parameters. To maintain
      the study blind, subjects will be blindfolded during study drug administration. The
      cardiologists at the central ECG laboratory (Spaulding Clinical Research, LLC) will be
      blinded to treatment, time, and study day/subject identifiers.

      Subjects who meet all of the following inclusion criteria will be eligible to participate in
      the study:

        1. Subject signs an Institutional Review Board (IRB) approved written informed consent and
           privacy language as per national regulations (e.g., Health Insurance Portability and
           Accountability Act [HIPAA] authorization for sites in the United States) before any
           study related procedures are performed.

        2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at least
           50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at Screening.

        3. Subject has normal medical history findings, clinical laboratory results, vital sign
           measurements, 12 lead ECG results, and physical examination findings at Screening or, if
           abnormal, the abnormality is not considered clinically significant (as determined and
           documented by the investigator or designee).

        4. Female subjects must be at least 2 years postmenopausal, surgically sterile or
           practicing 2 highly effective methods of birth control (as determined by the
           investigator or designee; one of the methods must be a barrier technique), and not
           pregnant or lactating before enrollment in the study.

        5. Male or female subjects must agree to practice 2 highly effective methods of birth
           control (as determined by the investigator or designee; one of the methods must be a
           barrier technique) from Screening until 30 days after the last dose of study drug.

        6. Subject is highly likely (as determined by the investigator) to comply with the
           protocol-defined procedures and to complete the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc</measure>
    <time_frame>24 hours</time_frame>
    <description>Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle</measure>
    <time_frame>24 hours</time_frame>
    <description>Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placebo, and Baseline-adjusted Changes in Ventricular Gradient</measure>
    <time_frame>24 hours</time_frame>
    <description>Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Relationship (Ratio) Between Heart Rate and QT</measure>
    <time_frame>24 hours</time_frame>
    <description>Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)</measure>
    <time_frame>24 hours</time_frame>
    <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Drug-induced Surface ECG Changes</condition>
  <arm_group>
    <arm_group_label>Ranolazine 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dofetilide 500mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dofetilide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil HCl 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verapamil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinidine sulfate 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quinidine sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <arm_group_label>Ranolazine 1500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dofetilide</intervention_name>
    <arm_group_label>Dofetilide 500mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <arm_group_label>Verapamil HCl 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine sulfate</intervention_name>
    <arm_group_label>Quinidine sulfate 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects who meet all of the following inclusion criteria will be
        eligible to participate in the study:

          1. Subject signs an IRB approved written informed consent and privacy language as per
             national regulations (e.g., Health Insurance Portability and Accountability Act
             [HIPAA] authorization for sites in the United States) before any study related
             procedures are performed.

          2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at
             least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at
             Screening.

          3. Subject has normal medical history findings, clinical laboratory results, vital sign
             measurements, 12 lead electrocardiogram (ECG) results, and physical examination
             findings at Screening or, if abnormal, the abnormality is not considered clinically
             significant (as determined and documented by the investigator or designee).

          4. Female subjects must be at least 2 years postmenopausal, surgically sterile or
             practicing 2 highly effective methods of birth control (as determined by the
             investigator or designee; one of the methods must be a barrier technique), and not
             pregnant or lactating before enrollment in the study.

          5. Male or female subjects must agree to practice 2 highly effective methods of birth
             control (as determined by the investigator or designee; one of the methods must be a
             barrier technique) from Screening until 30 days after the last dose of study drug.

          6. Subject is highly likely (as determined by the investigator) to comply with the
             protocol defined procedures and to complete the study.

        Exclusion Criteria:

          -  Subjects who meet any of the following exclusion criteria will not be eligible to
             participate in the study:

               1. Subject has a 12 lead safety ECG result at Screening or Check in of Period 1 with
                  evidence of any of the following abnormalities:

                    -  QTc using Fridericia correction (QTcF) &gt;450 milliseconds (ms) for men and
                       &gt;470 ms for women

                    -  PR interval &gt;220 ms

                    -  QRS duration &gt;110 ms

                    -  Second- or third-degree atrioventricular block

                    -  Complete left or right bundle branch block or incomplete right bundle branch
                       block

                    -  Heart rate &lt;40 or &gt;90 beats per minute

                    -  Pathological Q-waves (defined as Q wave &gt;40 ms)

                    -  Ventricular pre-excitation

               2. Subject has more than 12 to 20 ectopic beats during the 3 hour Holter ECG at
                  Screening.

               3. Subject has a history of unexplained syncope, structural heart disease, long QT
                  syndrome, heart failure, myocardial infarction, angina, unexplained cardiac
                  arrhythmia, torsades de pointes, ventricular tachycardia, or placement of a
                  pacemaker or implantable defibrillator. Subjects will also be excluded if there
                  is a family history of long QT syndrome (genetically proven or suggested by
                  sudden death of a close relative due to cardiac causes at a young age) or Brugada
                  syndrome.

               4. Subject has a history or current evidence of any clinically significant (as
                  determined by the investigator) cardiovascular, dermatologic, endocrine,
                  gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurologic,
                  psychiatric, pulmonary, renal, urologic, and/or other major disease or malignancy
                  (excluding nonmelanoma skin cancer). The investigator may allow exceptions to
                  these criteria (e.g., stable mild joint disease [that will not interfere with or
                  influence the leg raises/exercises required by the protocol, in the opinion of
                  the investigator], cholecystectomy, childhood asthma) following discussion with
                  the medical monitor.

               5. Subject has a history of thoracic surgery.

               6. Subject has any condition possibly affecting study drug absorption (e.g.,
                  gastrectomy, Crohn's disease, irritable bowel syndrome).

               7. Subject has a skin condition likely to compromise ECG electrode placement.

               8. Subject is a female with breast implants.

               9. Subject's laboratory test results at Screening or Check in of Period 1 are
                  outside the reference ranges provided by the clinical laboratory and considered
                  clinically significant (as determined and documented by the investigator or
                  designee).

              10. Subject's laboratory test results at Screening or Check in of Period 1 indicate
                  hypokalemia, hypocalcemia, or hypomagnesemia according to lower limits of the
                  reference ranges provided by the clinical laboratory.

              11. Subject's laboratory test results at Screening or Check in of Period 1 are &gt;2 ×
                  the upper limit of normal (ULN) for alanine aminotransferase or aspartate
                  aminotransferase, &gt;1.5 × ULN for bilirubin, or &gt;1.5 × ULN for creatinine.

              12. Subject has a positive test result at Screening for human immunodeficiency virus
                  antibody, hepatitis C antibodies, or hepatitis B surface antigen.

              13. Subject has a mean systolic blood pressure &lt;90 or &gt;140 mmHg or a mean diastolic
                  blood pressure &lt;50 or &gt;90 mmHg at either Screening or Check in of Period 1. Blood
                  pressure will be measured in triplicate after the subject has been resting in a
                  supine position for a minimum of 5 minutes.

              14. Subject has a known hypersensitivity to ranolazine, dofetilide, verapamil, or
                  quinidine or related compounds.

              15. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee,
                  chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours
                  before dosing or anticipates an inability to abstain from these products
                  throughout the duration of the study.

              16. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing
                  tobacco, snuff) within 6 weeks before Screening (self reported).

              17. Subject is unable to tolerate a controlled, quiet study conduct environment,
                  including avoidance of music, television, movies, games, and activities that may
                  cause excitement, emotional tension, or arousal during the prespecified time
                  points (e.g., before and during ECG extraction windows).

              18. Subject is unwilling to comply with study rules, including the study specific
                  diet, attempting to void at specified times (e.g., before ECG extraction
                  windows), remaining quiet, awake, undistracted, motionless, and supine during
                  specified times, and avoiding vigorous exercise as directed.

              19. Subject has a history of consuming more than 14 units of alcoholic beverages per
                  week within 6 months before Screening, has a history of alcoholism or
                  drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12
                  ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor), or has a
                  positive test result for alcohol or drugs of abuse (amphetamines, barbiturates,
                  benzodiazepines, cannabinoids, cocaine, and opiates) at Screening or Check in of
                  each period.

              20. Subject has used any prescription or nonprescription drugs within 14 days or 5
                  half lives (whichever is longer), or complementary and alternative medicines
                  within 28 days before the first dose of study drug (excluding oral
                  contraceptives, hormone replacement therapy, aspirin, ibuprofen, and
                  acetaminophen).

              21. Subject is currently participating in another clinical study of an
                  investigational drug or has been treated with any investigational drug within 30
                  days or 5 half lives (whichever is longer) of the compound.

              22. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or
                  more, or received a transfusion of any blood or blood products within 60 days, or
                  donated plasma within 7 days before Check in of Period 1.

              23. Subject has any other condition that precludes his or her participation in the
                  study (as determined by the investigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical Research LLC</affiliation>
  </overall_official>
  <results_reference>
    <citation>Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sørensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther. 2014 Nov;96(5):549-58. doi: 10.1038/clpt.2014.155. Epub 2014 Jul 23.</citation>
    <PMID>25054430</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss DG. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc. 2015 Apr 13;4(4). pii: e001615. doi: 10.1161/JAHA.114.001615.</citation>
    <PMID>25870186</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. J Electrocardiol. 2015 Nov-Dec;48(6):1081-7. doi: 10.1016/j.jelectrocard.2015.08.004. Epub 2015 Aug 4.</citation>
    <PMID>26324176</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <results_first_submitted>March 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2015</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Dofetilide</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>doi:10.13026/C2HP45</doc_id>
      <doc_type>ECG, PK and clinical information database</doc_type>
      <doc_url>https://physionet.org/physiobank/database/ecgrdvq/</doc_url>
      <doc_comment>This publicly available database contains raw and annotated ECG signals, PK measures as well as clinical information of this study.</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>52 healthy volunteers were assessed for eligibility. 24 subjects were excluded because they did not meet the inclusion criteria. 22 of 28 subjects who met the inclusion criteria were randomized and allocated to receive crossed-over intervention. Williams Latin square design balanced for first-order carryover effects was used for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine 1500 mg</title>
          <description>Single oral dose of Ranolazine 1500mg. Each subject received each drug only once in a randomized sequence (10 sequences in total).</description>
        </group>
        <group group_id="P2">
          <title>Dofetilide 500 mcg</title>
          <description>Single oral dose of Dofetilide 500mcg. Each subject received each drug only once in a randomized sequence (10 sequences in total).</description>
        </group>
        <group group_id="P3">
          <title>Verapamil HCl 120 mg</title>
          <description>Single oral dose of Verapamil HCl 120 mg. Each subject received each drug only once in a randomized sequence (10 sequences in total).</description>
        </group>
        <group group_id="P4">
          <title>Quinidine Sulfate 400 mg</title>
          <description>Single oral dose of Quinidine sulfate 400mg. Each subject received each drug only once in a randomized sequence (10 sequences in total).</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Single oral dose of Placebo (comparison group). Each subject received each drug only once in a randomized sequence (10 sequences in total).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive either ranolazine, dofetilide, verapamil, quinidine or placebo.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White / Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White / Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American / Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian / Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate</title>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PR interval</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.1" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QRS duration</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>J-Tpeakc (heart rate corrected J-Tpeak interval)</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225.6" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tpeak-Tend interval</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QTc (Fridericia's heart rate corrected QT interval)</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spatial QRS-T angle</title>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ventricular gradient</title>
          <units>mV*ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.4" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc</title>
        <description>Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O3">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
          <group group_id="O4">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc</title>
          <description>Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms)</description>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PR interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="1.1" upper_limit="11.8"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-3.0" upper_limit="7.6"/>
                    <measurement group_id="O3" value="32.1" lower_limit="26.7" upper_limit="37.4"/>
                    <measurement group_id="O4" value="5.1" lower_limit="-0.3" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QRS duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.5" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-1.1" upper_limit="3.3"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.4" upper_limit="4.8"/>
                    <measurement group_id="O4" value="2.1" lower_limit="-0.2" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in J-Tpeakc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="-3.4" upper_limit="9.9"/>
                    <measurement group_id="O2" value="39.5" lower_limit="32.8" upper_limit="46.2"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-9.0" upper_limit="4.3"/>
                    <measurement group_id="O4" value="29.1" lower_limit="22.4" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Tpeak-Tend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="1.9" upper_limit="15.8"/>
                    <measurement group_id="O2" value="40.0" lower_limit="33.0" upper_limit="46.9"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-2.2" upper_limit="11.7"/>
                    <measurement group_id="O4" value="49.8" lower_limit="42.8" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="5.5" upper_limit="19.6"/>
                    <measurement group_id="O2" value="79.3" lower_limit="72.2" upper_limit="86.3"/>
                    <measurement group_id="O3" value="5.2" lower_limit="-1.8" upper_limit="12.2"/>
                    <measurement group_id="O4" value="78.1" lower_limit="70.9" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>For each ECG biomarker and treatment, the null hypothesis is that there is no difference in the biomarker change from baseline between the treatment and placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>For each ECG biomarker and treatment, the placebo-corrected change from baseline was computed using linear mixed effect model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle</title>
        <description>Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O3">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
          <group group_id="O4">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle</title>
          <description>Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees)</description>
          <units>degrees</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-4.6" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-4.9" lower_limit="-7.2" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-4.4" upper_limit="0.3"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>For each ECG biomarker and treatment, the null hypothesis is that there is no difference in the biomarker change from baseline between the treatment and placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>For each ECG biomarker and treatment, the placebo-corrected change from baseline was computed using linear mixed effect model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Placebo, and Baseline-adjusted Changes in Ventricular Gradient</title>
        <description>Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms).</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O3">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
          <group group_id="O4">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo, and Baseline-adjusted Changes in Ventricular Gradient</title>
          <description>Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms).</description>
          <units>mV*ms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="-1.8" upper_limit="6.8"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.5" upper_limit="9.1"/>
                    <measurement group_id="O3" value="4.2" lower_limit="-0.1" upper_limit="8.5"/>
                    <measurement group_id="O4" value="6.0" lower_limit="1.6" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>For each ECG biomarker and treatment, the null hypothesis is that there is no difference in the biomarker change from baseline between the treatment and placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>For each ECG biomarker and treatment, the placebo-corrected change from baseline was computed using linear mixed effect model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Relationship (Ratio) Between Heart Rate and QT</title>
        <description>Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O3">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
          <group group_id="O4">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relationship (Ratio) Between Heart Rate and QT</title>
          <description>Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.02" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.02" upper_limit="0.09"/>
                    <measurement group_id="O3" value="0.02" lower_limit="-0.01" upper_limit="0.06"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.07" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O2">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
          <units>ms per ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="28.7" lower_limit="22.9" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" lower_limit="65.8" upper_limit="81.5"/>
                    <measurement group_id="O2" value="3.9" lower_limit="-0.7" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-1.7" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.8" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in J-Tpeakc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="31.6" upper_limit="46.6"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-4.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Tpeak-Tend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="26.9" upper_limit="42.0"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.9" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated.</description>
          <units>ms per mcg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.8" upper_limit="7.6"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-0.8" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="7.3" upper_limit="16.7"/>
                    <measurement group_id="O2" value="78.9" lower_limit="68.2" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-0.9" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in J-Tpeakc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-3.3" upper_limit="4.7"/>
                    <measurement group_id="O2" value="26.1" lower_limit="13.5" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Tpeak-Tend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="7.3" upper_limit="12.7"/>
                    <measurement group_id="O2" value="51.2" lower_limit="34.6" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O2">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
          <units>degrees per ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-5.4" upper_limit="-2.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.0" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated.</description>
          <units>degrees per mcg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.62" upper_limit="0.67"/>
                    <measurement group_id="O2" value="2.7" lower_limit="-0.3" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dofetilide 500mcg</title>
            <description>Single oral dose of Dofetilide 500mcg</description>
          </group>
          <group group_id="O2">
            <title>Verapamil HCl 120 mg</title>
            <description>Single oral dose of Verapamil HCl 120 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
          <units>mV.ns per ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.6" upper_limit="7.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-1.5" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
        <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine 1500mg</title>
            <description>Single oral dose of Ranolazine 1500mg</description>
          </group>
          <group group_id="O2">
            <title>Quinidine Sulfate 400mg</title>
            <description>Single oral dose of Quinidine sulfate 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)</title>
          <description>The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).
The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated.</description>
          <units>mV.ns per mcg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-3.8" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-2.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From May 2013 to July 2013</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine 1500mg</title>
          <description>Single oral dose of Ranolazine 1500mg</description>
        </group>
        <group group_id="E2">
          <title>Dofetilide 500mcg</title>
          <description>Single oral dose of Dofetilide 500mcg</description>
        </group>
        <group group_id="E3">
          <title>Verapamil HCl 120 mg</title>
          <description>Single oral dose of Verapamil HCl 120 mg</description>
        </group>
        <group group_id="E4">
          <title>Quinidine Sulfate 400mg</title>
          <description>Single oral dose of Quinidine sulfate 400mg</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Single oral dose of Placebo (comparison group)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David G Strauss, MD, PhD</name_or_title>
      <organization>U.S. Food and Drug Administration</organization>
      <phone>301-796-6323</phone>
      <email>david.strauss@fda.hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

